Vol.

No.

July 10, 2026Jul 10, 2026

DOWNLOAD THE PDF

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted. The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

Cover Story

News Analysis

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.

The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

By Jacquelyn Cobb

On Feb. 2, Nature Medicine published the results of a large, randomized, prospective clinical trial in the nascent and some say, fringe, field of chrono-oncology—the study of how natural biological rhythms might impact cancer outcomes.

Capitol Hill

OMB’s plan to increase political control of science faces stiff opposition on Capitol Hill

By Paul Goldberg

Clinical Trials & Tribulations

Saving Western Kenya’s pediatric blood cancer patients
How flow cytometry is changing the diagnostic landscape

By Samuel (Tony) Boova, Eda Holl, LaToya Montgomery, Steve Kussick, Nicholas Kigen, Gilbert Olbara, Festus Muigai Njuguna, Terry Vik and Teresa Loile Lotodo

Clinical Trials & Tribulations

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

By Enrique Velazquez-Villarreal

The long life of a clinical trial
How JCO sustains landmark oncology research

By Journal of Clinical Oncology

Cancer Policy

FDA halts public release of Complete Response Letters, following citizen petition

Cancer patients with Medicare Advantage have access to fewer providers than Medicare patients, cross-sectional study finds

CMS proposes end-of-life counseling provision, echoing ACA “death panels” controversy

FDA proposes rule to hold foreign tobacco companies to U.S. standards

In Brief

Ned Sharpless’s portrait unveiled at FNIH ceremony

ARPA-H awards up to $160M to advance personalized curative medicines for rare genetic diseases

Cancer Research Institute issues 93 awards totaling $37 million

Clinical Roundup

Zoldonrasib + daraxonrasib show 81% ORR in patients with RAS G12D metastatic pancreatic cancer, phase I/II study finds

HIF-2α inhibitor casdatifan yields 35% response rate in kidney cancer, phase I study finds

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

Should lowest-risk prostate cancer still be called “cancer”? UCLA-led study suggests changing the name could save lives

Equal access to cancer care removes race as predictor of survival, VA analysis finds

Sexual orientation, gender identity are key variables in cancer screening disparities, OSUCCC – James study finds

Tumor-on-a-chip model shows how pancreatic cancer hijacks immune cells, UMiami study finds

Cancer Research UK and partners announce new global phase II study in rare adrenal gland cancer

Drugs & Targets

European Commission grants marketing authorization for Tepkinly + R2 in R/R FL

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Volume 52 | Issue 34 - September 18, 2026